Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia

Michele Baccarani(University of Bologna), S Tura(University of Bologna), Giovanna Cavazzini(University of Padua), Renato Fanin(University of Udine), Alfonso Zaccaria(University of Bologna), Giuseppe Bandini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola)

Leukemia Research

January 1, 1983

10.1016/0145-2126(83)90048-6

Cited by 81

Related Papers

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

|Blood|2011|497

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

|Blood|2011|460

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

|Blood|2013|391

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

|Cancer Cell|2014|366

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

|Leukemia|2008|354